Clinical Trials Logo
  1. Home
  2. Uremic Pruritus
  3. NCT03576235

Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients — SNUG  

Uremic Pruritus Clinical Trial

Official title:
Safety and Efficacy of PG102P for the coNtrol of prUritus in Patients underGoing Hemodialysis (SNUG Trial): Study Protocol for a Randomized Control Trial

Clinical Trial Summary

In this study (SNUG trial), the investigators aim to investigate the anti-pruritic effect of PG102P in comparison with placebo in 80 patients undergoing HD.

Clinical Trial Description

This is a multicenter, randomized, double-blind, placebo-controlled trial in which one group will be treated with PG102P (1.5 g/day) and the other with a placebo. It is an investigator-initiated clinical trial. A superiority trial is planned to test the hypothesis that PG102P is effective in relieving pruritus for patients with ESRD undergoing HD. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03576235
Study type Interventional
Source Seoul National University Boramae Hospital
Contact
Status Completed
Phase N/A
Start date May 1, 2018
Completion date March 30, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04728984 - A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet Phase 3
Completed NCT02143973 - Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Terminated NCT01660243 - Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis Phase 2
Completed NCT06159686 - The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus Phase 1/Phase 2
Not yet recruiting NCT05525234 - A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus Phase 4
Completed NCT03002233 - TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus Phase 1
Completed NCT03998163 - CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 3
Active, not recruiting NCT05885737 - Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus Phase 3
Recruiting NCT04393675 - Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients Phase 1/Phase 2
Completed NCT05575193 - Acupressure on Uremic Pruritus and Sleep Quality Among Patients Receiving Hemodialysis N/A
Completed NCT02858726 - Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 2/Phase 3
Completed NCT02143648 - Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Completed NCT00494975 - The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease N/A
Recruiting NCT06446310 - Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus Phase 3
Completed NCT03758079 - Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus Phase 4
Completed NCT02229929 - Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus Phase 2
Completed NCT04639674 - AST-120 in Hemodialysis Patients With Uremic Pruritus Phase 4
Completed NCT03636269 - CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 3
Not yet recruiting NCT06466421 - Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis Phase 4
Completed NCT04711603 - A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. Phase 3